| Identification | Back Directory | [Name]
CIVENTICHEM CV-4057 | [CAS]
248281-84-7 | [Synonyms]
LAQ
CS-82
ABR 215062
ABR-215062
Lanquinimod
CIVENTICHEM
oro-N-ethyL
-2-oxo-N-phenyL
ine-3-carboxamide
Laquinimod, >=98%
-1,2-dihydroquinoL
-4-hydroxy-1-methyL
CIVENTICHEM CV-4057
ABR-215062 (Laquinimod)
LaquiniMod (ABR-215062)
Laquinimod potassium salt
ABR215062; ABR 215062 (LAQUINIMOD)
LaquiniMod, SAIK-MS coMpound, ABR-215062
5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
5-Chloro-N-Et-4-hydroxy-1-methyl-2-oxo-N-Ph-1,2-dihydroquinoline-3-carboxamide
5-Chloro-4-hydroxy-1-methyl-2-oxo-N-ethyl-N-phenyl-1,2-dihydroquinoline-3-carboxamide
5-chloro-N-ethyl-4-hydroxy-1-Methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxaMide
3-Quinolinecarboxamide, 5-chloro-N-ethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-
5-Chloro-4-hydroxy-1-Methyl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid ethyl-phenyl-aMide
LAQUINIMOD,5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-1,2-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID ETHYL-PHENYL-AMIDE
LaquiniMod,CiventicheMCV-4057,5-Chloro-4-hydroxy-1-Methyl-2-oxo-1,2-dihydroquinoline-3-carboxylicacidethylphenylaMide | [EINECS(EC#)]
692-155-1 | [Molecular Formula]
C19H17ClN2O3 | [MDL Number]
MFCD08689859 | [MOL File]
248281-84-7.mol | [Molecular Weight]
356.8 |
| Chemical Properties | Back Directory | [Melting point ]
201 °C (decomp) | [Boiling point ]
484.8±45.0 °C(Predicted) | [density ]
1.395±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
Soluble in DMSO (>25 mg/ml) | [form ]
solid | [pka]
4.50±1.00(Predicted) | [color ]
Off-white | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. | [InChI]
1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3 | [InChIKey]
GKWPCEFFIHSJOE-UHFFFAOYSA-N | [SMILES]
OC(C1=C(C=CC=C1N(C2=O)C)Cl)=C2C(N(C3=CC=CC=C3)CC)=O |
| Safety Data | Back Directory | [Hazard Codes ]
T | [Risk Statements ]
25 | [Safety Statements ]
45 | [RIDADR ]
UN 2811 6.1 / PGIII | [WGK Germany ]
WGK 1 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Carc. 2
Repr. 2
STOT RE 2 |
| Hazard Information | Back Directory | [Description]
Laquinimod (248281-84-7) is an immunomodulator1 that inhibits inflammation2 and autoimmunity3,4 via activation of the aryl hydrocarbon receptor (AhR)5. It has been investigated as a treatment for multiple sclerosis6 and has shown efficacy in Huntington’s disease models7,8. | [Uses]
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has?the?potential?for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases?research[1][2][3][4]. | [Definition]
ChEBI: Laquinimod is an aromatic amide. | [Synthesis]
b) To a stirred solution of anhydrous tetrahydrofuran (50 mL) of the compound (CAS:1379595-99-9) (10 mmol) was added sodium methanolate (3.6 mmol, 0.5 M, dissolved in methanol) in batches under nitrogen protection. The reaction mixture was heated to reflux for 2 hours. Upon completion of the reaction, the mixture was cooled and the solvent was partially evaporated to give a concentrated solution containing the insoluble salt. The concentrated solution was dissolved in a solvent mixture of methanol (30 mL), 10 M aqueous sodium hydroxide (1.07 mL, 10.7 mmol) and water (15.0 mL). Subsequently, 5 M aqueous hydrochloric acid (2.4 mL, 12.0 mmol) was slowly added to neutralize the reaction mixture. The precipitated crystalline precipitate was collected by filtration, washed with cold methanol and dried to afford the target product 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide in 87% yield and 98.9% purity. | [in vitro]
abr-215062 was shown to completely inhibit the development of murine acute experimental autoimmune encephalomyelitis (eae) [1]. | [in vivo]
abr-215062 dose-dependently inhibited disease and showed better disease inhibitory effects as compared to roquinimex (linomide). furthermore, abr-215062 inhibited the inflammation of both cd4+ t cells and macrophages into central nervous tissues [2]. | [IC 50]
NF-κB | [References]
J?nsson et al. (2004), Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders: Structure-Activity Relationship; Med. Chem. 47 2075
Rothhammer et al. (2021); Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS, Neurol. Neuroimmunol. Neuroinflamm., 8 e946
Pitarokoili et al. (2014), Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis; Neuroimmunol., 274 38
Ott et al. (2019), Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity; Neuroinflammation, 16 49
Kaye et al. (2016), Laquinimod arrests experimental autoimmune encephalitis by activating the aryl hydrocarbon receptor; Natl. Acad. Sci. USA., 113 E6145
Th?ne and Linker (2016), Laquinimod in the treatment of multiple sclerosis: a review of the data so far; Drug Des. Devel. Ther., 10 1111
Dobson et al. (2016), Laquinimod dampens hyperactive cytokine production in Huntington’s disease patient myeloid cells; Neurochem., 137 782
Garcia-Miralles et al. (2016), Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease; Rep., 6 31652 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
|